Quantum-Si Inc (NASDAQ: QSIAW)

Quantum-Si Incorporated is a life sciences company focused on proteomics research with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome. The company has developed a proprietary universal single-molecule detection platform that is applied to proteomics to enable next generation protein sequencing to sequence proteins in a massively parallel fashion. This platform includes the Platinum NGPS instrument, Platinum Analysis Software and consumable kits for use with the Platinum line of instruments. Quantum-Si began a controlled launch of the Platinum instrument in December 2022, started a controlled commercial launch in January 2023 and moved to a full commercial launch in the second quarter of 2024. In January 2025 the company announced the launch of the Platinum Pro benchtop sequencer with first shipments occurring in March 2025. The company continues to develop its next generation platform Proteus which is anticipated to launch by the end of 2026.

Quantum-Si generates revenue primarily through the sale of its instruments consumables and software. The company sells the Platinum and Platinum Pro sequencers which are priced at approximately eighty five thousand dollars and one hundred twenty thousand dollars respectively. Recurring revenue is derived from the sale of consumable kits that are required to run samples on the instruments including Library Preparation Kits Barcoding Kits and Sequencing Kits. Additionally the company offers the Platinum Analysis Software which provides automated data analysis and visualization workflows for users of the sequencing platforms. Revenue is also supported through service and support arrangements that accompany instrument sales and through collaborations with distribution partners such as Avantor in North America.

Quantum-Si occupies a niche within the broader life sciences tools market where it competes with established providers of proteomics technologies such as Agilent Technologies Bio-Rad Laboratories Danaher Luminex Merck KGaA and Thermo Fisher Scientific. The company differentiates itself through its single molecule kinetic detection technology which delivers amino acid level resolution without reliance on ensemble measurements. Its instruments are priced significantly lower than traditional mass spectrometry systems which often cost one million dollars or more per unit. The integrated Platinum Analysis Software simplifies data interpretation and reduces the need for specialized bioinformatics staff. Quantum-Si holds a robust intellectual property portfolio with four hundred two issued patents and three hundred forty eight pending applications as of December 31 2025 which provides a barrier to entry for potential competitors. The company strategy emphasizes accessibility by offering a low capital cost platform that includes automated workflows enabling adoption in both core laboratories and smaller research settings.

Quantum-Si serves a diverse customer base that includes academic research institutions biopharmaceutical companies contract development and manufacturing organizations government agencies and industrial laboratories. The company’s early access program engaged leading academic centers and key industry partners to validate its technology across various applications. While specific customer names are not disclosed in the filing the company indicates that its products are used for biomarker discovery disease detection pathway analysis immune response studies vaccine development and quality assurance and quality control workflows. The platform is intended for research use only although the data generated may support future diagnostic and therapeutic development efforts.